Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
8.57
-0.17 (-1.95%)
Sep 10, 2026, 2:35 PM CST
SHA:603520 Revenue
Zhejiang Starry Pharmaceutical had revenue of 703.00M CNY in the quarter ending June 30, 2026, a decrease of -1.25%. This brings the company's revenue in the last twelve months to 2.46B, up 1.85% year-over-year. In the year 2025, Zhejiang Starry Pharmaceutical had annual revenue of 2.45B with 4.07% growth.
Revenue (ttm)
2.46B
Revenue Growth
+1.85%
P/S Ratio
1.56
Revenue / Employee
1.29M
Employees
1,905
Market Cap
3.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45B | 95.55M | 4.07% |
| Dec 31, 2024 | 2.35B | 154.24M | 7.02% |
| Dec 31, 2023 | 2.20B | 64.75M | 3.04% |
| Dec 31, 2022 | 2.13B | 131.32M | 6.57% |
| Dec 31, 2021 | 2.00B | 632.83M | 46.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Tibet Weixinkang Medicine | 1.13B |
| Harbin Medisan Pharmaceutical | 805.09M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Newland Pharmaceutical | 710.55M |
| Shanghai Xiao Fang Pharmaceutical | 537.42M |
| Shaanxi Kanghui Pharmaceutical | 429.09M |